Table 1.
Characteristics of the study population.
| PD | CTR | P-value# | Tauo-pathies* | Non-PD Synucleino-pathies§ | |
|---|---|---|---|---|---|
| Patients (n) | 75 | 75 | 18 | 13 | |
| Age (years) | 70 (64–76) | 70 (62–79) | 0.77 | 71 (67–77) | 71 (66–78) |
| Male/female (% female) | 49/26 (34.7%) | 50/25 (33.3%) | 0.86 | 10/8 (44.4%) | 8/5 (38.5%) |
| H&Y stage | 3.0 (3.0–4.0) | NA | 4.0 (3.4–4.0) | 3.0 (3.0–4.0) | |
| Disease duration (years) | 7.0 (4.0–10.0) | NA | 2.5 (2.0–4.0) | 4.0 (2.0–6.0) | |
| UPDRS III | 45 (38–52) | NA | 39 (31–52) | 36 (27–54) | |
| Glaucoma n (%) | 1 (1.3%) | 4 (5.3%) | 0.17 | 0 (0.0%) | 0 (0.0%) |
| Macular degeneration (n) (%) | 1 (1.3%) | 1 (1.3%) | 1.00 | 1 (5.6%) | 0 (0.0%) |
| Cataract (n) (%) | 9 (12.0%) | 7 (9.3%) | 0.60 | 1 (5.6%) | 0 (0.0%) |
| Any other eye disease (n) (%) | 6 (8.0%) | 7 (9.3%) | 0.77 | 1 (5.6%) | 1 (7.7%) |
| Contact lenses n (%) | 3 (4.0%) | 1 (1.3%) | 0.31 | 0 (0.0%) | 0 (0.0%) |
| Medical eye drops n (%) | 5 (6.7%) | 6 (8.0%) | 0.75 | 2 (11.1%) | 0 (0.0%) |
| Lubricants (n) (%) | 10 (13.3%) | 4 (5.3%) | 0.09 | 2 (11.1%) | 0 (0.0%) |
Data is presented as median (25th– 75th percentile). PD = Parkinson’s disease, CTR = control subjects, NA = not applicable. UPDRS = Unified Parkinson’s Disease Rating Scale.
#P-values reported for the comparison of PD and CTR.
*Tauopathies including PSP n = 13, CBS n = 5.
§Synucleinopathies including MSA-C n = 2, MSA-P n = 11.